Olive oil has been demonstrated to enhance various cardiometabolic risk factors. However, to our knowledge, the association between olive oil intake and cortical and trabecular bone microarchitecture has never been evaluated in Spanish women. We aimed to examine the association between olive oil intake and cortical and trabecular bone microarchitecture. We analyzed 523 women aged 50 (9) year, range (23–81) year. Participants underwent dual-energy X-ray absorptiometry and peripheral quantitative computed tomography scans. Dietary intake of calcium, vitamin D, energy and olive oil (g/day) were assessed by a self-administered food frequency questionnaire (FFQ). After adjustment for potential confounding factors (calcium (mg/day), vitamin D (μg/day) energy (Kcal/day), age, body mass index (BMI) (kg/m²), menopausal status, and osteoporotic diagnosis (normal, osteopenia, or osteoporosis)), there were significant increases in volumetric bone mineral density (vBMD) (mg/cm³) (p < 0.01) in the group with a higher intake of olive oil. Total, trabecular and cortical bone density were positively correlated with olive oil intake. The dietary intake of olive oil was significantly associated with vBMD in multiple regression analysis; total density: olive oil intake (g/day) standardized β = 0.185 (p < 0.001), trabecular density: olive oil intake (g/day) standardized β = 0.186 (p < 0.001) and cortical density olive oil intake (g/day) standardized β = 0.114 (p = 0.008). We conclude that the dietary intake of olive oil is positively associated with a better vBMD in Spanish women.

Introducción: la obesidad se ha asociado a un riesgo aumentado de padecer preeclampsia e hipertensión arterial gestacional.Objetivos: determinar si el sobrepeso y/o la obesidad materna al inicio de la gestación se asocian a un incremento del riesgo de padecer algún estado hipertensivo del embarazo en una población del sur de España.Métodos: estudio de cohortes retrospectivo. Se estudiaron 4.711 casos en los cuales se había registrado el IMC al inicio de la gestación. Grupos de estudio: a) sobrepeso; y b) obesidad al inicio de la gestación (desglosada por tipo de obesidad). Grupo control: IMC normal al inicio de la gestación. Se calculó el riesgo de presentar estados hipertensivos del embarazo (EHE) en general, hipertensión arterial (HTA) gestacional, preeclampsia, HTA crónica y preeclampsia sobreañadida a HTA crónica.Resultados: el sobrepeso materno se asoció a un incremento del riesgo de padecer algún EHE (OR 2,04, IC 95%: 1,43-2,91) y a un incremento del riesgo de padecer HTA gestacional (OR 1,68, IC 95%: 1,03-2,72) e HTA crónica (OR: 3,70, IC 95%: 1,67-8,18). La obesidad materna se asoció a un incremento de padecer algún EHE (OR 3,54, IC 95% 2,65-4,73), HTA gestacional (OR 2,94, IC 95% 2-4,33), HTA crónica (OR 8,31, IC 95%: 4,23-16,42) y preeclampsia (OR 2,08, IC 95%: 1,12-3,87). En el análisis multivariante (ajustado por la paridad y edad materna), el sobrepeso se asoció a un riesgo aumentado de padecer HTA gestacional (OR:1,74, IC 95%: 1,06-2,85), HTA crónica (OR 3,76, IC 95% 1,69-8,35) y preeclampsia (OR 2,12, IC 95% 1,005-4,48); la obesidad también incrementó el riesgo de HTA gestacional (OR 2,40, IC 95% 1,39-4,13), HTA crónica (OR 17,96, IC 95% 8,78-36,76) y preeclampsia (OR 3,69, IC 95% 1,64-8,27). Conclusiones: el sobrepeso y la obesidad aumentan el riesgo de padecer EHE. El riesgo es signifi cativamente mayor conforme se incrementa el IMC (desde sobrepeso a obesidad grado 3).

Although numerous articles have found an association between alterations in thyroid function and the risk of gestational diabetes mellitus (GDM), other studies have failed to demonstrate this association. This may be due to the different cut-off points used to define subclinical hypothyroidism. We aim to clarify the role of thyroid stimulating hormone (TSH) level in GDM within pregnant women with normal free thyroxine (fT4) levels. This retrospective cohort study was performed in 6775 pregnant women. The association between TSH and GDM was assessed by bivariate and multivariate logistic regression. Pregnant women with subclinical hypothyroidism are at significantly greater risk for GDM when compared with euthyroid pregnant women (OR = 1.85; 95% CI = 1.36–2.52). We have also observed that TSH levels increase the risk of GDM within euthyroid pregnant women, since the TSH levels between 2.5 and 4.71 showed a higher risk of GDM than those whose TSH levels are between 0.31 and 2.49 (OR = 1.54; 95% CI = 1.28–1.84). In addition, pregnant women with positive thyroid antibodies have almost 2.5 times the risk of developing GDM (OR = 2.47; 95% CI = 1.57–3.89). Our results support that in pregnant women with normal fT4 levels, higher first trimester TSH level implies a higher risk of GDM.

Subclinical hypothyroidism is defined as an elevated thyroid-stimulating hormone level with a normal thyroxin level without signs or symptoms of hypothyroidism. Although it is well accepted that overt hypothyroidism has a deleterious impact on pregnancy, recent studies indicate that subclinical hypothyroidism may affect maternal and fetal health. Studies suggest an association between miscarriage and preterm delivery in euthyroid women positive for anti-peroxidase antibodies and/or anti-thyroglobulin antibodies. A proposal of a new set-point to diagnose SCH was recently published. The aim of this research was to determine the optimal thyroid-stimulating hormone cut-off point to screen for subclinical hypothyroidism in the first trimester of gestation in a population of our clinical area and to determine the diagnostic value of this screening test for detecting anti-thyroid peroxidase antibodies. This cross-sectional study determines the cutoff point for SCH screening and evaluates its usefulness to detect TPO Ab using the Receiver Operating Characteristics (ROC) curve. Prevalence of SCH was calculated using as cut-off 2.5 mIU/L, 4 mIU/L, and our TSH 97.5th percentile. The ability to detect positive anti-thyroglobulin antibodies (TG Ab) and anti-thyroid peroxidase antibodies (TPO Ab) in patients with levels of TSH >97.5th percentile was determined by ROC curves. The mean, range and standard deviation of TSH was 2.15 ± 1.34 mIU/L (range 0.03–8.82); FT4 was 1.18 ± 0.13 ng/dL (range 0.94–1.3); TG Ab was 89.87 ± 413.56 IU/mL (range 0.10–4000); and TPO Ab was 21.61 ± 46.27 IU/mL(range 0.10–412.4). The ROC. analysis of the ability of the TSH level to predict the presence of positive TPO Ab found an AUC of 0.563. In our population, the TSH cutoff value for gestational SCH screening is 4.7 mIU/L. Using the SEGO recommended 2.5 mIU/L TSH cut-off point, the prevalence of SCH is 37%. Applying the ATA 2017 recommended cutoff point of 4 mIU/L, the prevalence of SCH is 9.6%. Finally, when the cut-off of 4.7 mIU/L (our 97.5th centile) was used, the SCH prevalence is 5%. TSH levels in the first trimester of pregnancy are not useful to detect TPO Ab.